Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Optics Balzers acquires mso jena Mikroschichtoptik

Optics Balzers, a leading supplier of innovative optical thin-film components and assemblies, is continuing its growth in great strides. With its acquisition of “mso jena Mikroschichtoptik GmbH” in Jena, Germany, it is expanding its competencies and manufacturing technologies into a unique portfolio.

16 Mar 2010

Bovie Medical reports revenues totalling $6.5M for fourth-quarter 2009

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the fourth quarter and year ended December 31, 2009.

16 Mar 2010

Fraunhofer USA CMB receives $4.395M award from DARPA to develop H1N1 influenza vaccine

Fraunhofer USA Center for Molecular Biotechnology announced today that it has received a $4.395 million award from the Defense Advanced Research Projects Agency to develop a vaccine against H1N1 influenza virus using its plant-based production platform.

16 Mar 2010

InnerPulse selects Dassault Systemes' Abaqus FEA software

Dassault Systèmes, a world leader in 3D and Product Lifecycle Management (PLM) solutions, today announced that InnerPulse, a medical device company pioneering a novel technology for those patients with cardiac rhythm disorders, has selected Abaqus finite element analysis (FEA) software from the SIMULIA to assist in development of their technology designed in SolidWorks CAD software.

16 Mar 2010

Simcere Pharmaceutical Group report 15.5% sequential growth in fourth quarter revenues

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported unaudited financial results for the quarter and the fiscal year ended December 31, 2009.

16 Mar 2010

IMIX, Arcoma announce intended merger

IMIX, an end-user provider of superior digital radiography (DR) systems, and Arcoma, a leading supplier of medical radiology systems and sub-systems, announce a letter-of-intent to combine the two companies into a single holding company, IMIX Holding AB. The proposed combination will allow both companies to offer a comprehensive line of leading radiology systems and sub-systems to markets and customers around the world.

16 Mar 2010

Savient Pharmaceuticals resubmits KRYSTEXXA BLA

Savient Pharmaceuticals, Inc. announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA™ (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

16 Mar 2010

Lilly receives exclusive rights to commercialize Acrux's testosterone solution

Eli Lilly and Company and Acrux announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON™).

16 Mar 2010

Boston Scientific stops shipment and announces inventory retrieval of ICDs and CRT-Ds

Boston Scientific Corporation announced today that it has stopped shipment and is retrieving field inventory of all its implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds).

15 Mar 2010

Hemispherx Biopharma reports net loss of $13,438,000 for fiscal year 2009

Hemispherx Biopharma, Inc., announced its financial results for the fiscal year ended December 31, 2009. The net loss for the year (including non-cash charges) was approximately $13,438,000 or $0.12 per share as compared to a net loss of $12,219,000 or $0.16 per share in 2008.

15 Mar 2010

Patheon's first-quarter fiscal 2010 total revenues up 5.2%

Patheon a global provider of drug development and manufacturing services to the international pharmaceutical industry today announced results for its first quarter ended January 31, 2010. All amounts are in U.S. dollars unless otherwise indicated.

15 Mar 2010

Insmed posts net profit of $2.3M for fourth-quarter 2009

Insmed Inc., a biopharmaceutical company, today reported results for the fourth quarter and full-year ended December 31, 2009.

15 Mar 2010

IMIX, Sunstone Capital sign investment agreement

Sunstone Capital has signed an investment agreement with IMIX, an end-user provider of superior digital radiography (DR) systems for hospitals and specialist clinics. Simultaneously IMIX and ARCOMA AB, a leading OEM supplier of medical and radiology systems and sub-systems, have signed a Letter of Intent to combine the activities of the two companies in a single holding company, IMIX Holding AB. The combined company will become a leading global supplier of radiographic solutions.

15 Mar 2010

NDA for BYDUREON: FDA issues complete response letter

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for BYDUREON™ (exenatide for extended-release injectable suspension).

15 Mar 2010

AAPHP urges FDA to reclassify electronic cigarette as tobacco product

The American Association of Public Health Physicians submitted a petition to the US Food and Drug Administration on February 23rd in response to their official stance concerning electronic cigarettes.

15 Mar 2010

Orexigen Therapeutics, Patheon sign long-term agreement for commercial manufacturing of Contrave

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.

15 Mar 2010

Medafor, Magle Life Sciences of Sweden sign long-term raw material supply agreement

Medafor Inc. announced today that it has signed a long-term raw material supply agreement with Magle Life Sciences of Sweden, the supplier of the key powder component for Medafor’s patented MPH(R) (Microporous Polysaccharide Hemosphere) surgical product, which is used by surgeons to control bleeding in complex surgical operations.

15 Mar 2010

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today that the U.S. Food and Drug Administration has allowed an IND (Investigational New Drug) for the Company’s lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials.

15 Mar 2010

FDA accepts proposed proprietary name Exelbine for ADVENTRX Pharmaceuticals' ANX-530

ADVENTRX Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the proposed proprietary name "Exelbine™" for the Company's product candidate ANX-530 (vinorelbine injectable emulsion).

12 Mar 2010

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.

12 Mar 2010